Low-Dose Multivalent Vaccine Composition for Broad Variant Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing vaccines often require a minimum dose of antigen components to elicit an optimal immune response, and there is a need for compositions that can effectively prevent pathogens from diverse phylogenetic families like influenza and HIV.
Innovation Solution
A vaccine composition comprising a plurality of RNAs and viral-like particles that encode or display six or more homologous distinct antigen components with less than 98% sequence identity, present in specific amounts ranging from 1 ng to 5 micrograms, to induce an immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If multiple homologous antigen components are included in a vaccine composition, then broad protection against diverse pathogens is achieved, but the complexity of the composition increases
Solution Approach 1:
The vaccine composition is segmented into multiple discrete antigen components (six or more homologous distinct antigen components) that can be individually encoded by separate RNAs or displayed on separate viral-like particles. This segmentation allows each component to target specific pathogen variants while maintaining overall compositional manageability through modular design
Solution Approach 2:
The vaccine composition achieves multi-functionality by incorporating multiple homologous distinct antigen components that collectively provide broad protection against diverse pathogens from the same phylogenetic family. Each antigen component contributes to universal coverage while maintaining specificity for different variants
2Device complexity
If low doses of antigen components are used, then the vaccine composition simplicity is improved, but the immune response effectiveness may be compromised
Solution Approach 1:
Multiple antigen components are merged into a single vaccine composition where each component is present at low individual doses (1 ng to 5 micrograms). The combined effect of multiple low-dose components achieves broad immune coverage that would be difficult to attain with high doses of single components, thereby maintaining simplicity while ensuring effectiveness
Solution Approach 2:
The dose parameters for each antigen component are optimized to fall within the range of 1 ng to 5 micrograms. This parameter optimization ensures that each component elicits sufficient immune response at low doses, while the collective effect of multiple components provides comprehensive protection without requiring high individual doses
Data Source
AI summary
The present disclosure provides a vaccine composition comprising six or more homologous distinct antigen components. Any two of the six or more homologous distinct antigen components may share less than 98% or 95% sequence identity. The homologous distinct antigen components may comprise proteins. An amount of a protein in a dose of said human adult vaccine composition may be about 600 nanograms (ng) to about 3 micrograms (μg). The homologous distinct antigen components may comprise a plurality of RNA. An amount of an RNA of said plurality of RNA in a dose of said vaccine composition may be about 1 ng to about 5 μg per dose. The homologous distinct antigen components may comprise a plurality of proteins displayed on heterologous viral-like particles (VLPs). An amount of a protein displayed on a heterologous VLP of the plurality of proteins displayed on heterologous VLPs in a dose of the vaccine composition may be about 1 ng to about 5 μg per dose.